Returning search results with filters:
Remove filter forIssue: Health products
Remove filter forLast updated: 2022 Clear all
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 1 of 1 items.
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
… Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation … risk communication See Key Messages below 2022-01-07 Casirivimab and Imdevimab There is a high risk of treatment failure with the …
AlertHealth professional risk communication | 2022-01-07